CBT-004(C-Biomex)

N/A

Report date: 2025/11/20 16:04:57

NME

Base Information

Drug NameCBT-004(C-Biomex)

Drug Alias NameCBT-004(C-Biomex)

ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)Radiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionFibroblast activation protein alpha modulators

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesC-Biomex Ltd

China Registration ClassN/A

Develop Information

Active CompaniesC-Biomex Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A